These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 8509523)

  • 21. Biochemistry and pharmacology of reversible inhibitors of MAO-A agents: focus on moclobemide.
    Nair NP; Ahmed SK; Kin NM
    J Psychiatry Neurosci; 1993 Nov; 18(5):214-25. PubMed ID: 7905288
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A controlled double-blind trial of moclobemide and imipramine in the treatment of depression.
    Kok LP; Tsoi WF
    Singapore Med J; 1995 Feb; 36(1):38-40. PubMed ID: 7570133
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical, endocrine and neurochemical effects of moclobemide in depressed patients.
    Alevizos B; Hatzimanolis J; Markianos M; Stefanis CN
    Acta Psychiatr Scand; 1993 Apr; 87(4):285-90. PubMed ID: 8488751
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The predictive validity of atypical neurovegetative depressive symptoms identified by the first principal component in the DUAG trial of moclobemide versus clomipramine.
    Bech P; Stage KB; Larsen JK; Vestergaard P; Gram LF;
    J Affect Disord; 2012 Nov; 140(3):253-9. PubMed ID: 22381949
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination therapy using moclobemide with tricyclic and tetracyclic antidepressants to treat therapy-resistant depression.
    König F; Wolfersdorf M
    Pharmacopsychiatry; 1997 May; 30(3):93-6. PubMed ID: 9211570
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dimensional assessment of onset of action of antidepressants: a comparative study of moclobemide vs. clomipramine in depressed patients with blunted affect and psychomotor retardation.
    Jouvent R; Le Houezec J; Payan C; Mikkelsen H; Fermanian J; Millet V; Dufour H
    Psychiatry Res; 1998 Jul; 79(3):267-75. PubMed ID: 9704873
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Monoamine oxidase inhibitors in psychiatry. Status of current knowledge].
    Volz HP; Gleiter CH; Möller HJ
    Nervenarzt; 1996 May; 67(5):339-47. PubMed ID: 9005342
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antidepressant effect of Ro 11-1163, a new MAO inhibitor.
    Stefanis CN; Alevizos BH; Papadimitriou GN
    Int Pharmacopsychiatry; 1982; 17(1):43-8. PubMed ID: 7045018
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A double-blind placebo-controlled comparison of moclobemide and amitriptyline in the treatment of depression.
    Bakish D; Wiens A; Ellis J; Alda M; Lapierre Y
    Can J Psychiatry; 1992 Sep; 37 Suppl 1():12-7. PubMed ID: 1394026
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparison study of moclobemide and doxepin in major depression with special reference to effects on sexual dysfunction.
    Philipp M; Kohnen R; Benkert O
    Int Clin Psychopharmacol; 1993 Jan; 7(3-4):149-53. PubMed ID: 8468436
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Moclobemide].
    Gleiter C; Volz HP
    Dtsch Med Wochenschr; 1995 Aug; 120(34-35):1175-6. PubMed ID: 7656852
    [No Abstract]   [Full Text] [Related]  

  • 32. Moclobemide. A review of its pharmacological properties and therapeutic use in depressive illness.
    Fitton A; Faulds D; Goa KL
    Drugs; 1992 Apr; 43(4):561-96. PubMed ID: 1377119
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Major Depression Rating Scale (MDS). Inter-rater reliability and validity across different settings in randomized moclobemide trials. Danish University Antidepressant Group.
    Bech P; Stage KB; Nair NP; Larsen JK; Kragh-Sørensen P; Gjerris A
    J Affect Disord; 1997 Jan; 42(1):39-48. PubMed ID: 9089057
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Controlled comparison of RO 11-1163 (moclobemide) and placebo in the treatment of depression.
    Botte L; Evrard JL; Gilles C; Stenier P; Wolfrum C
    Acta Psychiatr Belg; 1992; 92(6):355-69. PubMed ID: 1345409
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Moclobemide for depression.
    Drug Ther Bull; 1994 Jan; 32(1):6-8. PubMed ID: 7635005
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Moclobemide in depression: a randomized, multicentre trial against isocarboxazide and clomipramine emphasizing atypical depression.
    Larsen JK; Gjerris A; Holm P; Anderson J; Bille A; Christensen EM; Høyer E; Jensen H; Mejlhede A; Langagergaard A
    Acta Psychiatr Scand; 1991 Dec; 84(6):564-70. PubMed ID: 1792931
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tryptophan and tyrosine ratios to neutral amino acids in endogenous depression. Relation to antidepressant response to amitriptyline and lithium + L-tryptophan.
    Møller SE; Honoré P; Larsen OB
    J Affect Disord; 1983 Feb; 5(1):67-79. PubMed ID: 6220046
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Moclobemide, imipramine, and placebo in the treatment of major depression (DSM III).
    Versiani M; Nardi AE; Mundim FD; Alves AB
    J Neural Transm Suppl; 1989; 28():65-75. PubMed ID: 2794994
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: effects on hemodynamics and catecholamine metabolism in healthy volunteers.
    Illi A; Sundberg S; Ojala-Karlsson P; Scheinin M; Gordin A
    Clin Pharmacol Ther; 1996 Apr; 59(4):450-7. PubMed ID: 8612391
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antidepressants, alcohol and psychomotor performance.
    Tiller JW
    Acta Psychiatr Scand Suppl; 1990; 360():13-7. PubMed ID: 2248062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.